Sanofi: Stronger Launches And A New R&D Reset Keep The Re-Rating Case Alive (NASDAQ:SNY)
· seekingalpha.com
Sanofi Q2 raises guidance as Dupixent drives 2026 outlook; faster launches diversify revenue.
In our last update, we provided a deep dive into Sanofi ( SNY ) ( SNYNF ) patent cliff and exposure to its major drug (Dupixent). We maintained our Buy rating d...